Literature DB >> 21595857

Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.

Elissa Charlotte Briggs1, Thuan Nguyen, Michael Abraham Wall, Kelvin David MacDonald.   

Abstract

INTRODUCTION: Cystic fibrosis (CF) pulmonary disease is characterized by intermittent episodes of acute lung symptoms known as 'pulmonary exacerbations'. While exacerbations are classically treated with parenteral antimicrobials, oral antibiotics are often used in 'mild' cases.
OBJECTIVES: We determined how often management progressed to intravenous (IV) therapy. We also examined multiple courses of oral antimicrobials within one exacerbation, and identified patient factors associated with unsuccessful treatment.
METHODS: We performed a retrospective chart audit of oral antibiotic use in CF patients, from March 2009 through March 2010, for 'mild' CF exacerbations.
RESULTS: Administration of a single vs multiple courses of oral antibiotics for treatment of 'mild' CF exacerbation avoided progression to IV therapy 79.8% and 50.0% of the time, respectively. Overall, oral antibiotics circumvented the need for IV therapy 73.8% of the time. Using multi-variant analysis, we found multiple patient characteristics to be independent risk factors for oral antibiotic failure including a history of pseudomonas infection [odds ratio (OR) 2.13, confidence interval (CI) 1.29-3.54], CF-related diabetes (OR 1.85, CI 1.00-3.41), allergic Bronchopulmonary aspergillosis (OR 3.81, CI 1.38-10.56), low socioeconomic status (OR 1.67, CI 1.04-2.67), and calculated baseline forced expiratory volume in 1 s (FEV1) < 75% of predicted prior to an acute exacerbation (OR 1.93, CI 1.20-3.08). Decline in FEV1 > 10%, weight for age, body mass index, distance from the CF center and gender were not significant.
CONCLUSION: Our observations suggest that one course of oral antimicrobials is frequently effective in outpatient CF pulmonary exacerbations but exacerbations requiring more than one course of oral antibiotics are likely to require IV therapy.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21595857      PMCID: PMC3934104          DOI: 10.1111/j.1752-699X.2011.00246.x

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  29 in total

1.  Genes in the vicinity of CFTR modulate the cystic fibrosis phenotype in highly concordant or discordant F508del homozygous sib pairs.

Authors:  Frauke Mekus; Ulrike Laabs; Henk Veeze; Burkhard Tümmler
Journal:  Hum Genet       Date:  2002-10-03       Impact factor: 4.132

2.  The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States.

Authors:  M S Schechter; B J Shelton; P A Margolis; S C Fitzsimmons
Journal:  Am J Respir Crit Care Med       Date:  2001-05       Impact factor: 21.405

3.  Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis.

Authors:  Maria T Britto; Uma R Kotagal; Richard W Hornung; Harry D Atherton; Joel Tsevat; Robert W Wilmott
Journal:  Chest       Date:  2002-01       Impact factor: 9.410

4.  Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.

Authors:  Don B Sanders; Rachel C L Bittner; Margaret Rosenfeld; Gregory J Redding; Christopher H Goss
Journal:  Pediatr Pulmonol       Date:  2010-10-21

Review 5.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

6.  Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Authors:  M E Hodson; C M Roberts; R J Butland; M J Smith; J C Batten
Journal:  Lancet       Date:  1987-01-31       Impact factor: 79.321

7.  Longitudinal changes in growth parameters are correlated with changes in pulmonary function in children with cystic fibrosis.

Authors:  Michelle L Peterson; David R Jacobs; Carlos E Milla
Journal:  Pediatrics       Date:  2003-09       Impact factor: 7.124

8.  Antibiotic treatment of Haemophilus influenzae and Haemophilus parainfluenzae infections in patients with cystic fibrosis.

Authors:  T Pressler; M Szaff; N Høiby
Journal:  Acta Paediatr Scand       Date:  1984-07

9.  Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis.

Authors:  M Szaff; N Høiby
Journal:  Acta Paediatr Scand       Date:  1982-09

10.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

View more
  9 in total

Review 1.  Cystic fibrosis chronic rhinosinusitis: a comprehensive review.

Authors:  Mohamad R Chaaban; Alexandra Kejner; Steven M Rowe; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2013 Sep-Oct       Impact factor: 2.467

Review 2.  Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review.

Authors:  Rosa María Girón Moreno; Marta García-Clemente; Layla Diab-Cáceres; Adrián Martínez-Vergara; Miguel Ángel Martínez-García; Rosa Mar Gómez-Punter
Journal:  Antibiotics (Basel)       Date:  2021-04-23

3.  Prognosis-Based Early Intervention Strategies to Resolve Exacerbation and Progressive Lung Function Decline in Cystic Fibrosis.

Authors:  Neeraj Vij
Journal:  J Pers Med       Date:  2021-02-03

4.  Dapagliflozin-lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic mice.

Authors:  Annika Åstrand; Cecilia Wingren; Audra Benjamin; John S Tregoning; James P Garnett; Helen Groves; Simren Gill; Maria Orogo-Wenn; Anders J Lundqvist; Dafydd Walters; David M Smith; John D Taylor; Emma H Baker; Deborah L Baines
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

5.  Evaluation of the Risk for Acute Kidney Injury in Adult Cystic Fibrosis Patients Receiving Concomitant Vancomycin and Tobramycin.

Authors:  Corinne Muirhead; Jeong Y Lim; Jodi Lapidus; Kelvin MacDonald
Journal:  Cureus       Date:  2017-12-06

6.  Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.

Authors:  Jordana E Hoppe; Brandie D Wagner; Frank J Accurso; Edith T Zemanick; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2018-06-18       Impact factor: 5.482

7.  One Center's Guide to Outpatient Management of Pediatric Cystic Fibrosis Acute Pulmonary Exacerbation.

Authors:  Corinne A Muirhead; Jillian N Sanford; Benjamin G McCullar; Dawn Nolt; Kelvin D MacDonald
Journal:  Clin Med Insights Pediatr       Date:  2016-07-12

Review 8.  Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape.

Authors:  Gemma E Stanford; Kavita Dave; Nicholas J Simmonds
Journal:  Chest       Date:  2020-09-20       Impact factor: 9.410

Review 9.  Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations.

Authors:  Garrett Pehote; Neeraj Vij
Journal:  Cells       Date:  2020-08-24       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.